Analyst Price Targets — NGNE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 28, 2026 10:09 am | — | Guggenheim | $69.00 | $27.05 | TheFly | Neurogene initiated with a Buy at Guggenheim |
| October 2, 2025 5:33 pm | — | H.C. Wainwright | $45.00 | $20.61 | TheFly | Neurogene looks 'deeply undervalued' after Taysha news, says H.C. Wainwright |
| April 14, 2025 11:53 am | Keith Tapper | BMO Capital | $16.00 | $10.89 | TheFly | Neurogene price target lowered to $16 from $45 at BMO Capital |
| March 25, 2025 11:01 am | Joel Beatty | Robert W. Baird | $38.00 | $14.20 | TheFly | Neurogene price target lowered to $38 from $46 at Baird |
| March 25, 2025 10:32 am | Mitchell Kapoor | H.C. Wainwright | $50.00 | $14.20 | TheFly | Neurogene price target lowered to $50 from $55 at H.C. Wainwright |
| November 20, 2024 9:53 pm | Paul Matteis | Stifel Nicolaus | $46.00 | $15.33 | StreetInsider | Neurogene (NGNE) PT Lowered to $46 at Stifel |
| November 19, 2024 9:02 pm | Keith Tapper | BMO Capital | $45.00 | $35.59 | StreetInsider | Neurogene (NGNE) PT Lowered to $45 at BMO Capital |
| November 12, 2024 2:09 pm | Keith Tapper | BMO Capital | $60.00 | $64.48 | StreetInsider | Neurogene (NGNE) PT Lowered to $60 at BMO Capital |
| November 12, 2024 2:04 pm | Paul Matteis | Stifel Nicolaus | $60.00 | $64.48 | StreetInsider | Neurogene (NGNE) PT Raised to $60 at Stifel |
| August 12, 2024 6:16 am | Mitchell Kapoor | H.C. Wainwright | $49.00 | $35.59 | TheFly | Neurogene price target lowered to $49 from $51 at H.C. Wainwright |
Latest News for NGNE
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an upcoming poster presentation that will demystify the intracerebroventricular (ICV) route of administration as a well-established, routinely performed neurosurgical procedure and a deliberate delivery…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience building…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company's common stock to four new…
Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced full year 2025 financial results and highlighted recent corporate updates. “We continue to demonstrate strong execution, with completion of enrollment in the Embolden registrational trial, dosing more than…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NGNE.
U.S. House Trading
No House trades found for NGNE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.